Double duty: Early research reveals how a single drug delivers twice the impact in fragile X - EurekAlert

A new study in Molecular Cell shows how two major pathways—AKT and NMD (nonsense-mediated mRNA decay)—interact in the context of fragile X syndrome. Researchers also found that Afuresertib, a drug currently being tested in phase 1 and 2 clinical trials for se…

image: Lynne Maquat, Ph.D., (standing) and Hana Cho, Ph.D., authors of a new study on a molecular mechanism behind fragile X syndrome.view more  Credit: University of Rochester Medical Center Like … [+5262 chars]

full article...